Catherine Scholz, Pharm.D.

Catherine Scholz brings over 20 years of experience in program leadership and global asset strategy, advancing programs in oncology and immunology from discovery through late-stage development. Prior to joining the Ikena team, Catherine was Senior Vice President, Program Management at Exo Therapeutics and has held leadership roles of increasing responsibility at H3 Biomedicine, Kura Oncology, EMD Serono, Takeda Oncology, and Bayer Schering Pharma. She was a key contributor to the global development and approvals of vedolizumab, brentuximab vedotin and estradiol valerate/dienogest. Catherine earned her B.S. and Doctor of Pharmacy from Rutgers University and completed her fellowship training in clinical pharmacology at the University of Texas, MD Anderson Cancer Center.